Spiracur and Century Medical Announce Multiple SNaP System Sales in Japan After Ministry of Health, Labor and Welfare Grants

Spiracur and Century Medical Announce Multiple SNaP System Sales in Japan After 
Ministry of Health, Labor and Welfare Grants
Proven Advanced Wound Care Device Offers Patients in Japan Effective,
Non-Powered Treatment for Chronic, Acute Wounds; Improves Quality of
SUNNYVALE, CA and TOKYO, JAPAN -- (Marketwired) -- 10/13/13 -- 
Spiracur Inc. and Century Medical, Inc. (CMI) today announced
multiple system sales of the SNaP(R) Wound Care System to hospitals
throughout Tokyo. Japan's Ministry of Health, Labor and Welfare
(MHLW) granted reimbursement pricing for a mechanically powered,
single-use Negative Pressure Wound Therapy (NPWT) device on July 1,
2013, and CMI began selling the ultraportable SNaP system to doctors
in Japan on August 1, 2013.  
Spiracur's SNAP System provides patients suffering from chronic or
acute wounds with a proven, advanced wound care solution that does
not require batteries or electricity. The device weighs 2.2 ounces/62
grams and is completely silent, offering patients discreet wound care
treatment that improves quality of life. 
"The SNaP System delivers an effective wound care therapy that heals
wounds faster than traditional dressings and does not interfere with
our patient's daily activities or sleep," said Kiyonori Harii, M.D.,
Professor Emeritus, University of Tokyo, and Chief Professor,
Department of Plastic & Reconstructive Surgery, Kyorin University
School of Medicine in Tokyo. "This new device provides tremendous
value because we are able to intervene in the wound healing process
earlier due to its ease-of-use and proven outcomes." 
"It is clear there was an unmet need in Japan until now, as the
response to the SNaP System has been overwhelmingly positive in just
two months of selling the groundbreaking system," said Mr. Akira
Hoshino, president and chief executive officer of Century Medical,
Inc. "We are very happy to be partnering with a successful American
company focused on the delivery of treatment to the patient. The SNaP
System's small size coupled with its proven efficacy offers Japanese
wound care practitioners a new, safe device for chronic and acute
wound care treatment while simultaneously improving patients' quality
of life."  
Spiracur is recognized for creating a new category of chronic and
acute wound management solutions. Several clinical studies have been
published supporting the SNaP Wound Care System as an effective
alternative to powered NPWT, including a comparative Randomized
Controlled Trial that also showed the powerful, small device makes a
positive difference in patients' quality of life.  
"We are thrilled to be able to offer the SNaP System to doctors,
wound care nurses and patients in Japan through our exclusive
distributor Century Medical," said Gary Restani, president and chief
executive officer for Spiracur Inc. "As evidenced by the immediate
demand for our wound care device, we are confident Japan will become
a very important market for the SNaP Wound Care System due to the
Japanese surgeons' dedication to improving chronic and acute wound
care treatment for patients." 
About Century Medical
 Century Medical, Inc. (CMI) is a wholly owned
subsidiary of ITOCHU Corporation (PINKSHEETS: ITOCY) and one of the
largest Japanese general trading companies with $125 billion in
annual trading transactions. CMI has more than 300 employees, offices
in eight major cities in Japan and 39 years' experience marketing
medical devices in Japan. CMI has been a pioneering force
successfully introducing many new technologies to the Japanese
healthcare community.  
About Spiracur Inc.
 Spiracur Inc., headquartered in Sunnyvale,
Calif., is a privately held medical device company focused on the
development of innovative wound healing technologies. Spiracur was
founded out of the Stanford University Biodesign Innovation Program
in 2007. Its first product, the SNaP Wound Care System for the
treatment of chronic and acute wounds, is the result of patient and
clinician feedback that powered negative pressure wound therapies
were too cumbersome. The company's ciSNaP(R) Closed Incision System
with proprietary controlled tension relief is designed to improve
healing of high-risk surgical incisions. Both devices have been
cleared by the U.S. Food & Drug Administration (FDA) and have
received CE Mark approval. For more information, please visit
Spiracur, Spiracur logo, SNaP, ciSNaP and SNaP & Design are
registered trademarks of Spiracur Inc. 
Media Contact: 
Amy Cook 
Investor Contact:
Steve Van Dick
Press spacebar to pause and continue. Press esc to stop.